XNAS
ABCL
Market cap3.69bUSD
Oct 08, Last price
12.02USD
1D
-6.31%
1Q
76.76%
IPO
-75.96%
Name
Abcellera Biologics Inc
Chart & performance
P/E
—
P/S
48.86
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.57%
Rev. gr., 5y
-20.27%
Revenues
75m
+160.56%
Net income
-146m
L-10.10%
CFO
-131m
L+20.95%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Key people
Carl Hansen
Chairman of the Board, President, Chief Executive Officer, Co-Founder · since 2012
Andrew Booth
Chief Financial Officer · since 2019
Tryn Stimart
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer · since 2023
Lead Independent Director · since 2019
Veronique Lecault
Co-Founder, Chief Operating Officer, Director · since 2019
Independent Director · since 2020
Stephen Quake
Independent Director · since 2025
Headquarters & legal address
1133 MELVILLE STREET SUITE 3500
THE STACK
VANCOUVER, BC V6E 4E5
CA
THE STACK
VANCOUVER, BC V6E 4E5
CA
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||